Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) General Information

Description

License for late-phase 3 oncology immunotherapy. The asset is a license for a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor-binding domain with diphtheria toxin fragments and is used for the treatment of cutaneous t-cell lymphoma and other cancer indications

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 8-2-337, Road Number Three
  • Banjara Hills
  • Hyderabad, Telangana 500034
  • India
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 8-2-337, Road Number Three
  • Banjara Hills
  • Hyderabad, Telangana 500034
  • India

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)‘s full profile, request access.

Request a free trial

Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)‘s full profile, request access.

Request a free trial

Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) FAQs

  • Where is Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) headquartered?

    Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) is headquartered in Hyderabad, India.

  • What industry is Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) in?

    Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)’s primary industry is Buildings and Property.

  • Is Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) a private or public company?

    Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) is a Private company.

  • What is the current valuation of Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)?

    The current valuation of Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) is .

  • What is Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)’s current revenue?

    The current revenue for Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) is .

  • Who are Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)’s investors?

    Dr. Reddy's has invested in Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777).

  • When was Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) acquired?

    Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) was acquired on 07-Sep-2021.

  • Who acquired Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)?

    Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) was acquired by Citius Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process